Segment change to Industry, Medical, Academia and Life Science from the fiscal year ending September 2024
First written in FY2023. 3 of 5 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Performance by segment is as follows.」
Reporting under the 3 segments of Industry, Medical, and Academia and Life Science continued in FY2025. - FY2025-H1RestatedAnnual report
「Operating results by segment are as follows.」
Reporting continued under the 3 segments of Industry, Medical, and Academia and Life Science, and the segment change from the first quarter of FY2024 was also applied to the current interim consolidated accounting period. - FY2024-Q2RestatedAnnual report
「The classification of reportable segments has been changed from the first quarter of the current fiscal year. For details, please refer to “3. Matters Relating to Changes, etc. in Reportable Segments” under “Segment Information” in “Part IV. Financial Information, 1. Quarterly Consolidated Financial Statements, Notes (Segment Information, etc.).”」
The segment change implemented from the first quarter of FY2024, from the former 4 segments to Industry, Medical, and Academia and Life Science, continued to apply in the second quarter. - FY2024-Q1AchievedAnnual report
「From the cumulative first quarter of the current fiscal year, the method of classifying business segments was reviewed in connection with changes to the company's organisational structure. The reportable segments were changed from the former "Chemical and Industrial Products," "Clinical Laboratory Reagents," "Food" and "Other" to "Industry," "Medical" and "Academia and Life Science."」
The segment change from the 4 segments previously announced for the fiscal year ending September 2024 was implemented from the first quarter of FY2024. Comparative information for the first quarter of the previous fiscal year was also prepared using the revised segment classifications. - FY2023First statedAnnual report
「The company changed its segments as follows from the fiscal year ending September 2024 in conjunction with an organizational restructuring. The restructuring was undertaken to achieve further efficiencies.」
The company indicated a policy of changing its reportable segments in the fiscal year ending September 2024 from the former Chemical Industrial Products, Clinical Laboratory Reagents, Food and Other segments to Industry, Medical, and Academia and Life Science.